Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.47 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | HCN1 | O60741 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023791 | 0.83 | PLK1 (0.50) | KCNK3KCNK9GAAPLK1RXFP1 | |
| SCHEMBL8317341 | 0.83 | KCNK3 (0.59) | KCNK3KCNK9F2RGAAPLK1 | |
| SCHEMBL22023693 | 0.82 | KCNK3 (0.43) | KCNK3KCNK9F2R | |
| SCHEMBL2061615 | 0.81 | KCNK3 (0.48) | KCNK3KCNK9F2RGAAPLK1 | |
| SCHEMBL22023672 | 0.76 | GAA (0.62) | GAAPLK1PDK2ALDH1A1MTNR1A | |
| SCHEMBL18530548 | 0.76 | PLK1 (0.49) | KCNK3KCNK9GAAPLK1RXFP1 | |
| SCHEMBL14892702 | 0.75 | KCNK3 (0.46) | KCNK3KCNK9F2RGAAPLK1 | |
| SCHEMBL22023937 | 0.74 | PLK1 (0.47) | GAAPLK1PDK2ALDH1A1MTNR1A | |
| SCHEMBL10252193 | 0.73 | ALDH1A1 (0.49) | KCNK3KCNK9F2RGAAPLK1 | |
| SCHEMBL201210 | 0.71 | KCNK3 (0.57) | KCNK3KCNK9F2RGAARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | KCNK3 4733/4885KCNK9 4644/4885F2R 2821/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | KCNK3 4733/4885KCNK9 4644/4885F2R 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.